ストックスクリーナーアプリを入手
23.15
0.81%
-0.19
アフターアワーズ：
23.15
前日終値:
$23.34
開ける：
$23.34
24時間の取引高:
821.07K
Relative Volume:
0.65
時価総額：
$2.85B
収益：
$460.48M
当期純損益:
$142.80M
株価収益率:
19.62
EPS:
1.18
ネットキャッシュフロー:
$221.79M
1週間 パフォーマンス:
-4.93%
1か月 パフォーマンス:
+2.34%
6か月 パフォーマンス:
+7.93%
1年 パフォーマンス:
+7.57%
1日の値動き範囲:
$22.93
$23.54
1週間の範囲:
$22.93
$24.45
52週間の値動き範囲:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
名前
Catalyst Pharmaceuticals Inc
セクター
電話
(305) 529-2522
住所
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.15 | 2.87B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-03-14 | 開始されました | Citigroup | Buy |
| 2024-03-07 | 開始されました | BofA Securities | Buy |
| 2023-12-21 | 開始されました | Oppenheimer | Outperform |
| 2022-08-24 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 再開されました | Piper Jaffray | Overweight |
| 2016-10-05 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2013-10-21 | 繰り返されました | Aegis Capital | Buy |
| 2013-09-24 | 開始されました | Maxim Group | Buy |
| 2013-09-06 | 繰り返されました | Aegis Capital | Buy |
| 2013-04-18 | 開始されました | Aegis Capital | Buy |
| 2012-08-27 | アップグレード | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | アップグレード | Merriman | Sell → Neutral |
| 2009-05-29 | ダウングレード | Hapoalim | Neutral → Underperform |
| 2009-05-29 | ダウングレード | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 開始されました | Merriman Curhan Ford | Buy |
| 2007-11-28 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 開始されました | Stifel Nicolaus | Buy |
| 2007-01-05 | 開始されました | First Albany | Buy |
すべてを表示
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
Aug PreEarnings: Is Catalyst Pharmaceuticals Inc CN2 stock a contrarian opportunityJuly 2025 Retail & Weekly High Return Forecasts - moha.gov.vn
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - Yahoo Finance
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - The Motley Fool
Aug Closing: Why Catalyst Pharmaceuticals Inc stock remains resilient2025 Earnings Surprises & AI Powered Market Entry Strategies - moha.gov.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade - ts2.tech
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Exchange Traded Concepts LLC Grows Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Voya Investment Management LLC Has $8.79 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Texas Permanent School Fund Corp Boosts Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Wedge Capital Management L L P NC Makes New $2.86 Million Investment in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains - 富途牛牛
First Week of February 2026 Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Market Fear: Can Catalyst Pharmaceuticals Inc. stock outperform in 2025 bull marketPortfolio Return Summary & AI Powered Market Entry Ideas - Улправда
Market Fear: Will Catalyst Pharmaceuticals Inc CN2 stock sustain bullish trend into 2025Quarterly Profit Review & Consistent Growth Stock Picks - moha.gov.vn
Can Catalyst Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Price Swings & Daily Momentum Trading Reports - Улправда
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now - MSN
Will Catalyst Pharmaceuticals Inc. stock see insider buyingPortfolio Performance Report & Fast Exit Strategy with Risk Control - Улправда
Why Catalyst Pharmaceuticals Inc. stock remains resilientQuarterly Market Summary & Safe Entry Momentum Stock Tips - DonanımHaber
What hedge fund moves indicate for Catalyst Pharmaceuticals Inc. (CN2) stock2025 Technical Patterns & Growth Focused Entry Reports - DonanımHaber
Assessing Catalyst Pharma After 600% Surge and Rare Disease Expansion in 2025 - Yahoo Finance
How A New US$200 Million Buyback At Catalyst Pharmaceuticals (CPRX) Has Changed Its Investment Story - Yahoo Finance
Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock - Benzinga
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Gains - Sahm
Catalyst Pharmaceuticals (NASDAQ:CPRX) Director Molly Harper Sells 26,746 Shares - MarketBeat
Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025 - ts2.tech
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Castleark Management LLC Sells 123,370 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Does Catalyst Pharmaceuticals Still Offer Value After Its 559.8% Five Year Surge in 2025? - Sahm
Is Catalyst Pharmaceuticals (CPRX) Still Undervalued After its Recent Multi‑Year Share Price Surge? - Yahoo Finance
Globeflex Capital L P Increases Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX) - Insider Monkey
JPMorgan Chase & Co. Buys 81,188 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Cresset Asset Management LLC Has $1.90 Million Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities CNS Therapeutics Virtual Conference 2025, Dec-08-2025 12 - marketscreener.com
How Investors Are Reacting To Catalyst Pharmaceuticals (CPRX) Upgraded 2025 Sales Outlook And Easing Short Interest - Sahm
Arrowstreet Capital Limited Partnership Purchases 188,594 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? - sharewise.com
Kennedy Capital Management LLC Cuts Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average - Finviz
Should I hold or sell Catalyst Pharmaceuticals Inc. stock in 2025Earnings Recap Report & Fast Moving Stock Watchlists - Newser
Is There Still Value in Catalyst Pharmaceuticals After Its 540% Five Year Surge? - Yahoo Finance
Catalyst: Firdapse Cliff Deferred, But Capital Allocation Still An Issue (Upgrade) (CPRX) - Seeking Alpha
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals (CPRX) chair reports gifts of company stock to family trusts - Stock Titan
Catalyst Pharmaceuticals Inc (CPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):